GORE® TAG® Thoracic Branch Endoprosthesis Zone 0/1 Post-Approval Study

Browse trials for

• Dissection, Thoracic Aorta 30
• Aneurysm, Aortic Arch 27

Keywords

• Zone 0
• Zone 1

Dissection, Thoracic Aorta

30 studies on the registry are indexed under Dissection, Thoracic Aorta; 10 are open to participants now.

This study's planned enrollment of 125 is above the median of 87 across 13 interventional studies indexed under Dissection, Thoracic Aorta.

Lead sponsor

W.L.Gore & Associates is the lead sponsor of 96 studies on the registry; 20 are open to participants now.

Study arms

• Other
  GORE® TAG® Thoracic Branch Endoprosthesis (TBE Device)

  Device: GORE® TAG® Thoracic Branch Endoprosthesis

Interventions

• DeviceGORE® TAG® Thoracic Branch Endoprosthesis

  Lesions in aortic arch in Zone 0 or Zone 1

Primary outcomes

1. Number of subjects with index endovascular procedure initiated after (or following) the surgical revascularization procedure

   Great vessel surgical revascularization procedure is completed, and the endovascular implantation procedure is initiated for the implantation of the TBE Device, without interim death or study discontinuation.

   Time frame: Index Endovascular Procedure Only

2. Device Technical Success (index procedure only)

   * Successful access, delivery, and accurate deployment of the device to the intended location, and retrieval of the delivery system. * Patency of the endovascular aortic and side branch components. * The absence of any unanticipated additional corrective procedure related to the device, procedure, or withdrawal of the delivery system.

   Time frame: Index Endovascular Procedure Only

3. Lesion-related mortality

   Death meeting at least one of the following characteristics: * Death during the hospitalization or within 30 days following the surgical revascularization procedure. * Death during the hospitalization or within 30 days following the index endovascular procedure or following conversion to open repair. * Death during the hospitalization or within 30 days following a complication from a secondary procedure associated with the index lesion or study device. * Any death where the treated disease / index lesion or study device caused or significantly contributed to the death, including lesion-rupture, aortic-related complications, disease progression involving the index lesion.

   Time frame: Within 30 days of surgical revascularization or within 30 days of index endovascular procedure

4. Disabling Stroke

   Stroke is the acute onset of symptoms consistent with focal or multifocal central nervous system (CNS) injury caused by vascular blockage resulting in ischemia or vascular rupture resulting in hemorrhage, that: * Is identified within 30-days following the surgical revascularization procedure or within 30-days following the index endovascular procedure -AND- * Persists for ≥ 24 hours or until death, or has symptoms lasting \< 24 hours, with pathology or neuroimaging confirmation of CNS infarction -AND- * Has an mRS ≥ 2 with an increase from baseline of at least one grade due to neurological deficits at no more than 120 days post index endovascular procedure.

   Time frame: Within 30 days of surgical revascularization or within 30 days of index endovascular procedure

5. Permanent Paraplegia (within 30-days)

   Paraplegia secondary to Spinal Cord Ischemia identified within 30 days following the index endovascular procedure combined with Spinal Cord Ischemia scale grade = 3 at the one-month follow-up visit. Paraplegia will be assessed using the SVS spinal cord ischemia grading system

   Time frame: Within 30 days of index endovascular procedure

6. Permanent Paraparesis (within 30-days)

   Paraparesis secondary to Spinal Cord Ischemia identified within 30 days following the index endovascular procedure, combined with Spinal Cord Ischemia scale grade = 2 at the one-month follow-up visit. Paraparesis will be assessed using the SVS spinal cord ischemia grading system.

   Time frame: Within 30 days of index endovascular procedure

7. New onset renal failure (within 30-days) requiring on-going dialysis

   New onset of sustained renal failure identified within 30 days following the index endovascular procedure, combined with requiring dialysis at the 1-Month follow-up visit.

   Time frame: Within 30 days of index endovascular procedure

8. Lesion rupture (treated area)

   Rupture in the treated segment of the vessel (e.g., aorta or branch) verified with direct observation or CT / CTA scan.

   Time frame: Minimum of 60 months and up to a maximum 120 months

9. Loss of aortic or branch patency

   No flow or contrast detected through the implanted aortic component or endovascular branch component confirmed with imaging and/or direct observation.

   Time frame: Minimum of 60 months and up to a maximum of 120 months

10. Endoleaks

    Perfusion of a treated lesion via: * Type I endoleak is defined as a sealing failure at one of the attachment zones of the graft to the vessel wall, whereby arterial flow perfuses the treated lesion via a perigraft channel: * Type Ia: Proximal aortic attachment zone * Type Ib: Distal aortic attachment zone * Type Ic: Distal attachment zone for branch component. * Type II: Retrograde flow from native aortic branch arteries. * Type III endoleak: Component disconnection or fabric disruption resulting in arterial flow into the perigraft space: * Type IIIa: Attachment of aortic components (aortic-aortic) * Type IIIb: Fabric tear or disruption * Type IIIc: Attachment of aortic component-side-branch or side-branch-side-branch. * Type IV: Late endoleak due to flow through porous fabric. * Type V/Endotension: Aneurysm sac enlargement \> 5 mm with no imaging evidence of an endoleak. * Indeterminate: Endoleak is identified, but source cannot be ascertained.

    Time frame: Minimum of 60 months and up to a maximum of 120 months

11. Reintervention

    Additional surgical or interventional procedure related to the treated disease / index lesion, the study device, or to the treatment / procedure. This may include surgical or interventional treatment for endoleaks, disease progression, procedures on the branch to improve or restore patency, spinal drains for Spinal Cord Injury (SCI) management, or conversion to open surgery. Events will not include access site(s) complications, interventions to address issues related to non-treated area of the index lesion, such as bare stent implantation to address bowel ischemia associated with aortic dissection.

    Time frame: Minimum of 60 months and up to a maximum of 120 months

Secondary outcomes

1. Access-related complications (index endovascular procedure only)

   Complications associated with the access sites used during treatment and any subsequent unplanned access-related reinterventions. This may include pseudoaneurysm, thrombosis, or complications associated with percutaneous closure devices.

   Time frame: Index endovascular procedure only

2. Life threatening bleed (index endovascular procedure only)

   An event associated with the index endovascular procedure leading to any of the following events as prior to discharge: * Overt bleeding requiring a transfusion of ≥5 units of whole blood/red blood cells within 48 hours of index endovascular procedure. * Cardiac tamponade * Overt bleeding requiring reoperation, surgical exploration, or reintervention for the purpose of controlling bleeding * Bleeding requiring intravenous vasoactive drugs * Fatal bleeding is bleeding that directly causes death with no other explainable cause

   Time frame: Index endovascular procedure only

3. Stroke

   Stroke is the acute onset of symptoms consistent with focal or multifocal central nervous system (CNS) injury caused by vascular blockage resulting in ischemia or vascular rupture resulting in hemorrhage, that: * Persists for ≥ 24 hours or until death -OR- * Symptoms lasting \< 24 hours, with pathology or neuroimaging confirmation of CNS infarction. Disabling stroke will be determined based on mRS ≥ 2 with an increase from baseline of at least one grade due to neurological deficits at no more than 120 days following the suspected stroke event.

   Time frame: Minimum of 60 months and up to a maximum of 120 months

4. Transient Ischemic Attack (TIA)

   Transient focal neurological signs or symptoms (lasting \< 24 h) presumed to be due to focal brain ischemia but without evidence of acute infarction by neuroimaging or pathology (or in the absence of imaging).

   Time frame: Minimum of 60 months and up to a maximum of 120 months

5. Paraplegia (within 30-days)

   Paraplegia secondary to Spinal Cord Ischemia identified within 30 days following the index endovascular procedure. Paraplegia will be assessed using the SVS spinal cord ischemia grading system.

   Time frame: Within 30 days of index endovascular procedure

6. Paraparesis (within 30-days)

   Paraparesis secondary to Spinal Cord Ischemia identified within 30 days following the index endovascular procedure. Paraparesis will be assessed using the SVS spinal cord ischemia grading system.

   Time frame: Within 30 days of index endovascular procedure

7. Distal device-related thromboembolic adverse event requiring intervention or surgery (through 1-Month)

   Device-related ischemic events in tissues distal to the device implantation site resulting in bypass, open surgical or transcatheter intervention, limb amputation, or leading to death.

   Time frame: Through 1 Month of index endovascular procedure

8. Myocardial infarction (within 30-days)

   Elevated CK-MB (≥ 10x ULN) measured within 48 hours following the surgical revascularization or index endovascular procedure or need for urgent or emergent PCI/CABG within 30-days following the surgical revascularization or index endovascular procedure as confirmed at the 1-Month follow-up visit.

   Time frame: Within 30 days of surgical revascularization procedure or within 30 days of index endovascular procedure

9. Laryngeal or Phrenic Nerve injury (within 30-days)

   Irreversible laryngeal nerve injury or phrenic nerve injury requiring unplanned surgery or intervention within 30-days following the surgical revascularization or index endovascular procedure as confirmed at the 1-Month follow-up visit.

   Time frame: Within 30 days of surgical revascularization or within 30 days of index endovascular procedure

10. Fistula formation

    Fistula detected between the aorta and any adjacent structure associated with the area treated with the endovascular stent graft system verified with direct observation or CT scan.

    Time frame: Minimum of 60 months and up to a maximum of 120 months

11. Upper extremity ischemia

    Clinically reported, device-related ischemia (Serious Adverse Event) not evident at the time of the index procedure with CTA-verified branch vessel compromise (i.e., malperfusion).

    Time frame: Minimum of 60 months and up to a maximum of 120 months

12. Lesion enlargement (treated area)

    An increase in maximum vessel (e.g., aorta or treated branch) diameter of \> 5 mm in the treated region as compared to baseline using orthogonal (i.e., perpendicular to the centerline) measurements on CT / CTA scans

    Time frame: Minimum of 60 months and up to maximum of 120 months

13. Device migration

    Longitudinal movement of all or part of the device for a distance ≥ 10 mm, as confirmed by CTA scan, relative to anatomical landmarks and device positioning at the first post-operative CTA scan.

    Time frame: Minimum of 60 months and up to a maximum of 120 months

14. New dissection (with / without treatment)

    A new arterial tear that was not present at the time of initial presentation caused either by a stent graft, natural disease progression or iatrogenic injury during the endovascular procedure. This can include the propagation, or extension, of a previous dissection.

    Time frame: Minimum of 60 months and up to maximum of 120 months

15. Device integrity events (e.g., fracture, kinking, compression)

    Defined as any of the following: * Wire fractures * Stent kinking: Narrowing of the stent graft associated with demonstrable angulation in any of the stent components, with demonstrable flow * Disruption / tears in the graft component of the stent graft * Stent compression or invagination: Transient or permanent stent graft collapse following complete device deployment, resulting in an overall reduction in the vessel luminal diameter

    Time frame: Minimum of 60 months and up to maximum of 120 months

16. False lumen status (dissection pathology)

    Status of the false lumen both within and outside of the segment of the aorta initially treated with an endovascular stent graft: * Patent: Flow present throughout the entire aortic false lumen (absence of thrombus) on arterial-phase or delayed contrast-enhanced imaging. * Partial thrombosis: Thrombus or clot within the aortic false lumen but with a residual patent flow channel on arterial-phase or delayed contrast-enhanced imaging. * Complete thrombosis: Complete thrombosis of the aortic false lumen on arterial- and delayed-phase imaging.

    Time frame: Minimum of 60 months and up to maximum of 120 months

17. False lumen perfusion (dissection pathology)

    Flow into the false lumen via: * Type IA entry flow: Flow between the proximal endograft and aortic wall allowing systemic pressure antegrade flow into the primary entry tear and proximal false lumen. * Type IB entry flow: Distal entry tear adjacent to endograft due to septal fenestration or a new intimal tear at the distal aspect of the stent graft (dSINE) allowing systemic pressure direct flow into the false lumen. * Type II entry flow: Retrograde entry flow through arch vessel branches (innominate, carotid, subclavian) or thoracic bronchial and intercostal arteries into the false lumen. * Type R entry flow: Antegrade entry flow from the true lumen into the false lumen through distal branch fenestrations (uncovered intercostal arteries, visceral or renal arteries, lumbar arteries, iliac branches) or septal fenestrations (excluding SINE).

    Time frame: Minimum of 60 months and up to maximum of 120 months

Individual participant data

Plan to share: Yes — Study Protocol

Supporting information: Study protocol